Herantis Pharma begins Recruitment for CDNF Trial

Herantis Pharma begins Recruitment for CDNF Trial
Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study.  CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis. Recruitment ... read more
Source: Published on 2018-03-05